As a Black woman who has seen cancer take a heavy toll in our communities, hearing my own diagnosis was terrifying.
Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...
Could a simple blood test predict your risk of getting dementia years, or even decades, before you experience memory loss?
In 2022, Arizona was one of the first states in the nation to pass legislation (House Bill 2144) requiring Medicaid and commercial insurance plans to cover qualified biomarker tes ...
However, definitive diagnosis evaded him, "We didn't go out and get a PET scan or a spinal tap, which would actually reveal if you actually have the plaques, because those tests were not covered by my ...
Siemens Healthineers announced today its offerings for brain health research are expanding, with the brain-derived, fully ...
13don MSN
Tennessee bill to expand biomarker testing coverage delayed after committee runs out of time
At the Tennessee Capitol, patients, advocates and families came prepared on Tuesday afternoon to tell lawmakers something simple: the right test at the right time can save a life.
Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...
Precision medicine relies on biomarker testing to match therapies to specific cancers, yet many patients remain untested due to standardization issues. Recommendations include educating clinicians, ...
5don MSN
New state law requires insurance coverage for biomarker testing for Alzheimer’s, cancer patients
Now, with the passing of House Bill 565, also known as Jill’s Law, all Mississippians will have access to biomarker testing ...
Gov. Tate Reeves has signed a bill requiring state-regulated health insurance plans in Mississippi to cover biomarker testing for certain conditions.
—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results